AxoGen, Inc. (AXGN)

[Bruce the Stock Guy]

Load zone!

[dog turd cannon]

And now down to $32.00... and it'll keep falling.

[dog turd cannon]

I don't see it at all.

Not even paying attention to it anymore. ASNS, OPHT, EDGE (scam play), .... there are too many easy 100-250% plays every month to go back into AXGN. I am not an investor. Just a trader.

Next time I find something juicy I'll try and let you know.

[Tearex]

3-45 ='s free shares.
How do you see AXGn 3 years from now?

[dog turd cannon]

It would appear reloading in that range was premature.

[dog turd cannon]

No. My money is better spent elsewhere. There are plenty of stocks below $3.00 ready to move up to 45 again why re-enter here?

[Bruce the Stock Guy]

AXGN..I wont sell this beast until the 100’s..

[Prudent Capitalist]

Hope you reloaded down in the $36 - $38 range prior to the surge back upward. The pullback was a great opportunity to accumulate more AXGN shares and add to positions here.

[Prudent Capitalist]

+3.93%. Nice day here for AXGN, with the upward trend clearly having resumed following the pullback. We have likely built a stronger base here. This is a long term holding for me and I expect it to eventually trade over $100.

[Prudent Capitalist]

AXGN is holding up nicely here, and is still up huge over the past several years, in spite of the pullback after it ran too far too fast.

[Tearex]

Cheers! $$$
Schooled and saved from FIT* at the same time as well.

Between the two,has created a whole new retirement account.

Thanks! Kept 50 for sentiment.

[dog turd cannon]

Down from 50+ to 39... ouch.

[dog turd cannon]

Wow, the guy that posted about $AXGN at 2.65 and then posted to sell at 52.00... was right!

Go figure...

[Lynx5100]

What are you expecting tonight

[Bruce the Stock Guy]

AXGN..Beast!

[Lynx5100]

I spoke to investor relations on this this was a disgruntled employee they were very well aware of it

[dog turd cannon]

No, not at all.

And it's down 20% since I sold.

[jimmybob]

60%+ in 8-12 months isn't much of a return on capital? Either way, nice exit for you.

Seems some rumors floating around on it friday... long runway of growth means nothing without employees... :(

Could be worth keeping yourself hedged just in case pic.twitter.com/RXCZjCyKev

— Anthony Thorpe (安東尼) (@200xEBITDA) July 27, 2018

[dog turd cannon]

I am out already. Even if you are right that isn't much a return on the capital here. I can get that return with much less risk at this point. But, it's considerably down from when I sold anyways.

[Prudent Capitalist]

Not at all likely. AXGN should continue to steadily climb just as it has for a number of years, and it appears to have much more room to run to the upside.

[manisero66]

Overpriced. Expecting a long deep fall.

[jimmybob]

$80-120 in the next 12-18 months

[jimmybob]

$AXGN $56.20s what a monster

[rajaram46]

Anybody looked at LMAT? Thoughts?

[Bruce the Stock Guy]

AXGN..SAVAGE!

[Bruce the Stock Guy]

AXGN..Monster!

[dog turd cannon]

It is time to sell. There is too much meat on this for me. Good luck.

[jimmybob]

ROcking! and Rolling!

[Prudent Capitalist]

Another new all time high here today for AXGN. That $70 price target is way too low the way things are going. AXGN appears to be headed north to "Franklinland"

[Thedeadman]

Axgn isn't even close to being done.

[jimmybob]

AxoGen price target raised to $70 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for AxoGen to $70 from $45, while reiterating an Outperform rating on the shares. AxoGen remains one of his favorite long-term small cap growth stories capable of sustaining a 44%-plus 5-year CAGR as the analyst sees significant runway ahead for increased adoption in a large underpenetrated existing commercially targeted $2.2B "core" peripheral nerve repair market opportunity, and thinks this TAM will soon be expanding to $3B-plus as the company begins to target the use of its products in the surgical management of pain in 2019

[Prudent Capitalist]

Way too early to sell any of my AXGN shares right now. Still in the very early stages of this investment situation, and there is considerable potential for further sharp increases in the share price. This is a very long term holding for me at this point.

[dog turd cannon]

It's just under $50.00 now. Soon it'll be time to sell. But, not yet.

[jimmybob]

haha :)

[Prudent Capitalist]

So much for that new $45 price target. LOL!

[jimmybob]

Congrats! No competition... AXGN is on an empty runaway for the next 6-8 years possiibly

[jimmybob]

$AXGN $49s dude

[Prudent Capitalist]

Another new all time high here today. I love my AXGN. Acquired initial position here in the $4 range and have held ever since. And, no plans to sell here as I have seen projections of AXGN ultimately being a $100 stock.

[Bruce the Stock Guy]

AXGN..Beast..

[Prudent Capitalist]

AxoGen, Inc. Announces Repayment in Full of its $25 million Outstanding Debt

https://ih.advfn.com/p.php?pid=nmona&article=77537418

[jimmybob]

A monster....

[jimmybob]

AxoGen remains a 'best in medtech story,' says Jefferies
While expectation might have been for more than 41% growth in Q1, AxoGen spent the first part of the quarter adding new sales management, new specialists, and generally investing in sales across the board, Jefferies analyst Raj Denhoy tells investors in a post-earnings research note. Despite the "noise," the company still posted 41% overall growth and guidance remains for a least 40% growth this year, with the emphasis on "at least," the analyst adds. He believes AxoGen remains a "best in medtech story" and keeps a Buy rating on the shares with a $45 price target

[jimmybob]

AxoGen price target raised to $45 from $37 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for AxoGen to $45 saying the "solid" Q1 sets the stage for a "strong" 2018. Although the beat was modest, AxoGen "weathered disruption from changes to its sales force in January and quickly rebounded with a record March," Bijou tells investors in a post-earnings research note. The analyst, however, thinks expectations may have gotten too high and that the stock may be under pressure. He views any pullback as a buying opportunity and reiterates an Overweight rating on AxoGen

[Prudent Capitalist]

It never will pull back, and will continue to move much higher. This company and its nerve regeneration science and technology are on the cutting edge and still in the very early stages.

[Bruce the Stock Guy]

AXGN..Wish I had bought more earlier..This stock is a beast! Wanted to add on a pullback but it never pulls back..

[Bruce the Stock Guy]

AXGN..Awesome buys..I’m in much much higher(embarrassed to say)..Gl!

[Prudent Capitalist]

Yes it is. Has been a great investment for me, as I got in around $4, and plan to hold for the long term. Thankfully it is in a tax deferred retirement account.

[Bruce the Stock Guy]

$AXGN..So STRONG!

[Bruce the Stock Guy]

$100<<<<AXGN..I can see it..Its a one of kind company!

[Prudent Capitalist]

+18% today due to the positive earnings report and surprise and the beat on revenues. Someone here a few years back predicted AXGN would go to $100 and they are in all likelihood correct. Longer term it will exceed that level, IMO.